Cantitate/Preț
Produs
Total produse
Vezi coșul
Blood–Brain Barrier in Drug Discovery – Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs de L Di

Blood–Brain Barrier in Drug Discovery – Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs

Autor L Di
en Limba Engleză Hardback – 26 ian 2015
Focused on central nervous system (CNS) drug discovery efforts, this book educates drug researchers about the blood-brain barrier (BBB) so they can affect important improvements in one of the most significant and most challenging areas of drug discovery.
Citește tot Restrânge

Preț: 94023 lei

Preț vechi: 98971 lei
-5% Nou

Puncte Express: 1410
Preț estimativ în valută:
16638€ • 19510$ • 14611£

Carte tipărită la comandă

Livrare economică 03-17 februarie 26

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9781118788356
ISBN-10: 1118788354
Pagini: 608
Dimensiuni: 164 x 243 x 38 mm
Greutate: 0.92 kg
Editura: Wiley
Locul publicării:Hoboken, United States

Public țintă

Central nervous system (CNS) drug discovery scientists, brain researchers, neuroscientists, drug metabolism and pharmacokinetic scientists, medicinal chemists, modelling and simulation scientists, biologists, pharmacologists, biochemists, biophysicists, toxicologists, pharmaceutical scientists, analytical chemists, graduate students, and postdoctoral fellows
Brain, neuroscience, pharmaceutical research, CNS drug discovery, brain drug disposition, pharmacokinetics

Notă biografică

Li Di is an associate research fellow in the Pharmacokinetics, Dynamics, and Drug Metabolism Department at Pfizer Global Research and Development and has extensive experience in the pharmaceutical industry. She has over 100 publications, presented over 70 invited lectures, and teaches an American Chemical Society short course on drug-like properties. Edward Kerns worked in pharmaceutical research and development for over 30 years, was associate director at Wyeth and Bristol-Myers Squibb, then was at the NIH-National Center for Advancing Translational Sciences. He published over 90 journal papers or book chapters and 3 books, and teaches an American Chemical Society short course on drug-like properties.